Marine anticancer agents: An overview with a particular focus on their chemical classes

Simple item page
dc.contributor.authorBarreca M.
dc.contributor.authorSpanò V.
dc.contributor.authorMontalbano A.
dc.contributor.authorCueto M.
dc.contributor.authorDíaz Marrero A.R.
dc.contributor.authorDeniz I.
dc.contributor.authorErdoğan A.
dc.contributor.authorBilela L.L.
dc.contributor.authorMoulin C.
dc.contributor.authorTaffin-De-Givenchy E.
dc.contributor.authorSpriano F.
dc.contributor.authorPerale G.
dc.contributor.authorMehiri M.
dc.contributor.authorRotter A.
dc.contributor.authorThomas O.P.
dc.contributor.authorBarraja P.
dc.contributor.authorGaudêncio S.P.
dc.contributor.authorBertoni F.
dc.date.accessioned2024-07-22T08:06:55Z
dc.date.available2024-07-22T08:06:55Z
dc.date.issued2020
dc.description.abstractThe marine environment is a rich source of biologically active molecules for the treatment of human diseases, especially cancer. The adaptation to unique environmental conditions led marine organisms to evolve different pathways than their terrestrial counterparts, thus producing unique chemicals with a broad diversity and complexity. So far, more than 36,000 compounds have been isolated from marine micro- and macro-organisms including but not limited to fungi, bacteria, microalgae, macroalgae, sponges, corals, mollusks and tunicates, with hundreds of new marine natural products (MNPs) being discovered every year. Marine-based pharmaceuticals have started to impact modern pharmacology and different anti-cancer drugs derived from marine compounds have been approved for clinical use, such as: cytarabine, vidarabine, nelarabine (prodrug of ara-G), fludarabine phosphate (pro-drug of ara-A), trabectedin, eribulin mesylate, brentuximab vedotin, polatuzumab vedotin, enfortumab vedotin, belantamab mafodotin, plitidepsin, and lurbinectedin. This review focuses on the bioactive molecules derived from the marine environment with anticancer activity, discussing their families, origin, structural features and therapeutic use. © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
dc.identifier.DOI-ID10.3390/md18120619
dc.identifier.issn16603397
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/13760
dc.language.isoEnglish
dc.publisherMDPI
dc.rightsAll Open Access; Gold Open Access
dc.subjectAnimals
dc.subjectAntineoplastic Agents
dc.subjectAquatic Organisms
dc.subjectBiological Products
dc.subjectDrug Discovery
dc.subjectHumans
dc.subjectMarine Toxins
dc.subjectNeoplasms
dc.subjectWater Microbiology
dc.subjectags 16c3f
dc.subjectalt p 7
dc.subjectantineoplastic agent
dc.subjectbrentuximab vedotin
dc.subjectcx 2029
dc.subjectcytarabine
dc.subjectdehydrodidemnin B
dc.subjectdepatuxizumab mafodotin
dc.subjectdolastatin
dc.subjectenapotamab vedotin
dc.subjectenfortumab vedotin
dc.subjecteribulin
dc.subjectfludarabine phosphate
dc.subjectfs 1502
dc.subjectfucoidin
dc.subjecthalichondrin B
dc.subjectladiratuzumab vedotin
dc.subjectlurbinectedin
dc.subjectmarine drug
dc.subjectmidostaurin
dc.subjectnatural product
dc.subjectnelarabine
dc.subjectplinabulin
dc.subjectpolatuzumab vedotin
dc.subjectrc 88
dc.subjectsalinosporamide A
dc.subjectsalinosporamide B
dc.subjectsalinosporamide D
dc.subjectsalinosporamide E
dc.subjectsalinosporamide F
dc.subjectsalinosporamide I
dc.subjectsalinosporamide J
dc.subjectsgn cd 228a
dc.subjectstaurosporine
dc.subjecttelisotuzumab vedotin
dc.subjecttisotumab vedotin
dc.subjecttrabectedin
dc.subjectunclassified drug
dc.subjectantineoplastic agent
dc.subjectbiological product
dc.subjectmarine toxin
dc.subjectantineoplastic activity
dc.subjectapoptosis
dc.subjectbiodiversity
dc.subjectcancer cell
dc.subjectdrug approval
dc.subjectdrug cytotoxicity
dc.subjectdrug design
dc.subjectdrug determination
dc.subjectdrug isolation
dc.subjectdrug screening
dc.subjectdrug structure
dc.subjectdrug synthesis
dc.subjecthuman
dc.subjectmarine environment
dc.subjectmarine species
dc.subjectnonhuman
dc.subjectReview
dc.subjectstructure activity relation
dc.subjectanimal
dc.subjectaquatic species
dc.subjectchemistry
dc.subjectdrug development
dc.subjectmicrobiology
dc.subjectneoplasm
dc.titleMarine anticancer agents: An overview with a particular focus on their chemical classes
dc.typeReview

Files

Collections

Scopus Koleksiyonu